Thursday 05 October 2023 | 22:40 US FDA panel gives thumbs down on approval for Amgen lung cancer drug Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial was not reliable enough to support traditional approval of Amgen’s AMGN.... By Reuters News Service
